<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636230</url>
  </required_header>
  <id_info>
    <org_study_id>RP-006</org_study_id>
    <nct_id>NCT03636230</nct_id>
  </id_info>
  <brief_title>Remote Patient Management of CIEDs - Brady Devices</brief_title>
  <acronym>RPM CIED Brady</acronym>
  <official_title>Remote Patient Management of Cardiac Implantable Electronic Devices - Brady Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ratika Parkash</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      While remote monitoring (RM) technology is currently available and has permitted surveillance&#xD;
      and device assessment from any patient location, the use has been inconsistent in Canada,&#xD;
      where only 8500 out of a potential 120 000 patients with cardiac implantable electronic&#xD;
      devices (CIEDs) are enrolled in this program. This technology is in widespread use worldwide&#xD;
      for all CIEDs but in Canada, it is utilized primarily for implantable defibrillators, but not&#xD;
      pacemakers. Whereas most of the trials were designed to evaluate the efficacy of RM in&#xD;
      implantable cardioverter defibrillator (ICD) patients, in the pacemaker (PM) population,&#xD;
      there has been work performed already to demonstrate an increase in detection of frequency of&#xD;
      adverse clinical events and a reduction in reaction time to those events by RM. Based on all&#xD;
      the available literature, it appears that RM benefits both patients and healthcare systems.&#xD;
      Overall, studies have demonstrated that RM can be used safely in all device&#xD;
      patient-populations, with the exception of pacemaker-dependent patients.&#xD;
&#xD;
      There have been no studies that have evaluated RM only follow up, nor have there been any&#xD;
      studies evaluating pacemaker-dependent patients. This study that will safely assess the use&#xD;
      of RM only, with in-clinic visits when necessary, that uses the patient-centered electronic&#xD;
      platform developed by the Cardiac Arrhythmia Network of Canada (CANet) to perform PM follow&#xD;
      up safely, in a more cost-effective manner.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Canadian multicenter randomized controlled trial to assess remote patient&#xD;
      management. Patients will be randomized in a 1:1 fashion, stratified by pacemaker dependence&#xD;
      and by center to either remote patient management of standard of care.&#xD;
&#xD;
      Remote patient management (intervention group):&#xD;
&#xD;
        -  Patients will be followed by remote monitoring only. Transmissions will occur at six&#xD;
           monthly intervals, with no in-clinic visits. If there is an actionable event on the&#xD;
           remote transmission, patients will be seen at their closest community device clinic. The&#xD;
           proposed intervention would eliminate any routine visits.&#xD;
&#xD;
        -  Newly implanted pacemaker patients will be seen after the initial implant at the hub&#xD;
           site, within 48 hours and then within 3 months to optimize programming for subsequent RM&#xD;
           visits. Thereafter, all follow-up will occur through remote monitoring every six months.&#xD;
           Unscheduled remote transmissions may also occur. Using a combination of remote&#xD;
           monitoring, and novel technology, VIRTUES, patients will be managed outside of the&#xD;
           clinic.&#xD;
&#xD;
        -  Patients will be provided with real-time knowledge of success of their remote&#xD;
           transmission and the status of the remote through a web-based portal called VIRTUES.&#xD;
&#xD;
        -  Virtual patient record - all patient information in the intervention arm will be&#xD;
           contained within an information cloud that will be accessible by patients; access to&#xD;
           their own data may be granted by the patient themselves to permit delivery of care&#xD;
           remotely, and to permit after hours follow up to be performed by the on call personnel.&#xD;
&#xD;
      Standard of care (comparison group):&#xD;
&#xD;
      The standard arm will be required to have in-clinic visits at yearly intervals. These&#xD;
      patients would not have access to the virtual patient cloud or to remote monitoring.&#xD;
&#xD;
      Pacemaker programming: All patients in both arms will undergo programming as per the ASSERT&#xD;
      II protocol (previously published) to optimize pacemaker parameters and detection of atrial&#xD;
      and ventricular high rate episodes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open label, 1:1 randomized trial, stratified by site and pacemaker dependence</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to major adverse cardiac event (primary safety outcome)</measure>
    <time_frame>18 months</time_frame>
    <description>Time to major adverse events (death, stroke, hospitalization for a cardiovascular cause, syncope or device-related emergency department visits). Survival free from the primary outcome will be estimated by the Kaplan-Meier method and compared, using the log-rank test. Cox proportional hazard regression analysis will be used to estimate the likelihood of survival, after verifying the proportional hazard assumption.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cost effectiveness</measure>
    <time_frame>18 months</time_frame>
    <description>Analysis will take the form of a cost utility analysis with cost effectiveness assessed in terms of the incremental cost per quality life year (QALY). Analysis will incorporate data on resource use and patient's utility values for the period from initiation of remote patient management to 12 months follow-up. Resource use associated with the remote patient management strategy will be estimated through detailed microcosting and will be contrasted with the costs of standard monitoring.&#xD;
QALYs will be estimated using the standard area under the cover methodology, controlling for baseline utility. Total costs and QALYs for each patient will be estimated with multiple imputation for missing data. The incremental costs and QALYs and incremental cost effectiveness ratios associated with remote patient management and the uncertainty around these will be derived through non-parametric bootstrapping.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Short Form (SF36)</measure>
    <time_frame>18 months</time_frame>
    <description>The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.&#xD;
The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Florida Patient Acceptance Survey (FPAS)</measure>
    <time_frame>18 months</time_frame>
    <description>The FPAS produces scores that range from 0-100, where higher scores indicate increased device acceptance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Florida Shock Anxiety Scale (FSAS)</measure>
    <time_frame>18 months</time_frame>
    <description>The FSAS produces scores that range from 10-50. Higher scores signify increased shock anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Brief Illness Perception Questionnaire (BIPQ)</measure>
    <time_frame>18 months</time_frame>
    <description>Individual item analysis will be used in this study. The personal control score is the response to item 3. The treatment control score is the response to item 4. Illness concern is measured by item 6. This reflects a combination of emotional and cognitive representations. Scores on these individual items range from 0-10 where higher scores on personal and treatment concern are reflected in higher scores. Higher scores on illness concern are reflected in higher scores.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">848</enrollment>
  <condition>Pacemaker</condition>
  <arm_group>
    <arm_group_label>Remote Patient Management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remote monitoring only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In-clinic visits</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Remote Monitoring</intervention_name>
    <description>Remote Monitoring only</description>
    <arm_group_label>Remote Patient Management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>In-Clinic visits only</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a Medtronic or Abbott pacemaker capable of remote monitoring.&#xD;
&#xD;
          -  Able to provide consent.&#xD;
&#xD;
          -  Access to a Smartphone or Tablet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No access to a family physician or general practioner&#xD;
&#xD;
          -  Unreliable autocapture function by device in pacemaker dependent patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ratika Parkash, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nova Scotia Health Authority</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ratika Parkash, MD FRCPC</last_name>
    <phone>902 473 4474</phone>
    <email>ratika.parkash@nshealth.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Giddens</last_name>
    <phone>902 473 2758</phone>
    <email>karen.giddens@nshealth.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial University of Newfoundland Hospital</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Hunt</last_name>
    </contact>
    <investigator>
      <last_name>Stephen Duffett, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Giddens</last_name>
      <phone>902 473-2758</phone>
      <email>karen.giddens@nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Amir AbdelWahab, MBBCh, MSc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Mary's General Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Radyk</last_name>
    </contact>
    <investigator>
      <last_name>Umjeet Jolly, MBBS, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Sacre Coeur</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Langlois</last_name>
    </contact>
    <investigator>
      <last_name>Marcio Sturmer, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paule Banville</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle Nault, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Ratika Parkash</investigator_full_name>
    <investigator_title>Staff Cardiologist Electrophysiologist</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

